Kendle Acquires Latin American CRO

Kendle has entered into agreements to acquire Latin America CRO, International Clinical Research Ltd. and related companies, adding to its global clinical development capabilities in the Phase II-IV arena through new operations in Argentina, Brazil, Colombia and Chile. The move supports the company’s strategic business expansion in high-growth regions to deliver global trials for its biopharmaceutical customers, and builds on existing capabilities in Mexico and Peru. The acquisition is the culmination of an ongoing relationship between Kendle and International Clinical Research, in which the two companies have worked together in recent years on drug development programs in Latin America.

“We are thrilled to be able to offer our customers the benefit of expanded reach and expertise in Latin America for their global clinical trials,” said Candace Kendle, Pharm.D., chairman and chief executive officer. “This acquisition builds on our thriving operations in the region and positions Kendle to drive future growth in our global clinical development business.”

Financial terms of the agreement were not disclosed. The transaction is expected to be complete in the second quarter. The acquired operations will operate under the Kendle name and will report to Dennis Hurley, Dr.Sc., vice president, global clinical development, Latin America.

International Clinical Research Ltd. was founded in 2002 by Raul Bozzo, M.D., and has approximately 25 clinical associates offering CRO and biopharma industry experience in Phase II-IV development, with significant therapeutic strengths in cardiovascular, oncology, central nervous system, endocrinology, infectious disease and pain/inflammation. Upon completion of the acquisition, Dr. Bozzo will assume the role of medical director, Latin America and country manager for Argentina and Chile. Mariagabriela Alterio, M.S., and Alcione Braga will serve as country managers for the new operations in Colombia and Brazil, respectively.

“We are excited to join Kendle,” said Dr. Bozzo, “We believe this merger will provide great benefit to our customers, to our associates, and to the development of clinical research in Latin America. Joining a global organization opens a world of opportunity for us. Kendle’s reach will bring a wider variety of trials to the region, and our highly specialized staff and country-specific expertise will add value to Kendle’s Latin America operations.”